Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Hisamitsu Pharmaceutical Co ( (JP:4530) ).
Hisamitsu Pharmaceutical Co. reported a slight decline in its consolidated financial results for the second quarter of the fiscal year ending February 28, 2026, with net sales decreasing by 0.7% and a notable drop in profit attributable to owners of the parent by 22.8%. Despite the decline, the company announced an increase in its annual dividend forecast, including a commemorative dividend for the anniversary of its MOHRUS Tapes, indicating a commitment to shareholder returns.
The most recent analyst rating on (JP:4530) stock is a Buy with a Yen4677.00 price target. To see the full list of analyst forecasts on Hisamitsu Pharmaceutical Co stock, see the JP:4530 Stock Forecast page.
More about Hisamitsu Pharmaceutical Co
Hisamitsu Pharmaceutical Co., Inc. operates in the pharmaceutical industry, primarily focusing on the development and sale of transdermal therapeutic products. The company is known for its products such as SALONPAS and MOHRUS Tapes, which are widely used for pain relief.
Average Trading Volume: 195,200
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen303.7B
For detailed information about 4530 stock, go to TipRanks’ Stock Analysis page.